Premium
Long‐term outcome of re‐irradiation for recurrent or second primary head and neck cancer: A multi‐institutional study of AIRO—Head and Neck working group
Author(s) -
Orlandi Ester,
Bonomo Pierluigi,
Ferella Letizia,
D'Angelo Elisa,
Maddalo Marta,
Alterio Daniela,
Infante Gabriele,
Bacigalupo Almalina,
Arge Angela,
Iacovelli Nicola Alessandro,
Desideri Isacco,
Meduri Bruno,
Triggiani Luca,
Volpe Stefania,
Belgioia Liliana,
Dionisi Francesco,
Romanello Domenico Attilio,
Fallai Carlo,
Miceli Rosalba
Publication year - 2019
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.25890
Subject(s) - head and neck cancer , medicine , cohort , proportional hazards model , head and neck , population , retrospective cohort study , survival analysis , oncology , radiation therapy , surgery , environmental health
Background To report the long‐term outcome of patients undergoing re‐irradiation (re‐RT) for a recurrent or second primary head and neck cancer (RSPHNCs) in seven Italian tertiary centers, while testing the Multi‐Institution Reirradation (MIRI) recursive partitioning analysis (RPA) recently published. Methods We retrospectively analyzed 159 patients. Prognostic factors for overall survival (OS) selected by a random forest model were included in a multivariable Cox analysis. To externally validate MIRI RPA, we estimated the Kaplan‐Meier group‐stratified OS curves for the whole population. Results Five‐year OS was 43.5% (median follow‐up: 49.9 months). Nasopharyngeal site, no organ dysfunction, and re‐RT volume <36 cm 3 were independent factors for better OS. By applying the MIRI RPA to our cohort, a Harrell C‐Index of 0.526 was found indicating poor discriminative ability. Conclusion Our data reinforce the survival benefit of Re‐RT for selected patients with RSPHNC. MIRI RPA was not validated in our population.